ArticleCancers2026
PP2A Activation as a Senotherapeutic in Neuroblastoma.
Nazia Nazam, Sorina N Shirley, Joel C Opara, Shamza Manzoor, Maryam G Shaikh, Morgan L Brown, Pranava Nande, Ali M Eakes, Abdulraheem Kaimari, Jianmei W Leavenworth and 2 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Nazia NazamDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-0517-6841 Sorina N ShirleyDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Joel C OparaDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Shamza ManzoorDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Maryam G ShaikhDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Morgan L BrownDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-2729-8244 Pranava NandeDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Ali M EakesDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-8970-7349 Abdulraheem KaimariDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Jianmei W LeavenworthDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Elizabeth A BeierleDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-4613-0527 Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8MSurgical Oncology Research Training ProgramT32CA229102 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERBERT CHEN · 2018 to 2026
$3.2MDirect Activation of PP2A as a Novel Approach to Group-3 Medulloblastoma TherapyR43CA268329 · NCI · ATUX ISKAY GROUP LLC · PI OHLMEYER, MICHAEL · 2022 to 2022
$407kSBIR PHASE I TOPIC #446 - DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT75N91023C00038 · NCI · ATUX ISKAY GROUP LLC · PI OHLMEYER, MICHAEL · 2023 to 2023
$400kSBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS75N91024C00009 · NCI · ATUX ISKAY GROUP LLC · PI OHLMEYER, MICHAEL · 2024 to 2024
$355kKaul Pediatric Research Institute NANCI NIH HHS 75N91023C00038NCI NIH HHS 75N91024C00009NCI NIH HHS P30 CA013148NCI NIH HHS R43 CA268329NCI NIH HHS T32 CA229102NIGMS NIH HHS T32 GM008361NIH HHS 1P20CA910232-25NIH HHS 1T32CA229102-24NIH HHS 2R43CA268329-24NIH HHS 5T32GM008361-25Rally Foundation for Childhood Cancer Research NAVince Lombardi Cancer Foundation NA
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
neuroblastomaPP2Asenescence-associated secretory phenotype (SASP)therapy-induced senescence (TIS)topotecan
Identifiers
PMID42882783
PMCPMC13664173
What OpenQuestion holds
Textmetadata
Read underepoch 390